View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
July 14, 2021

Seegene launches new test to identify SARS-CoV-2 variants

The Allplex SARS-CoV-2 Variants II Assay, which received CE mark last month, can help detect ten major Covid-19 variants.

South Korea-based biotech Seegene has introduced a new multiplex polymerase chain reaction (PCR) test that can screen for six emerging SARS-CoV-2 variants, including the Delta and Delta Plus variants.

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

The Allplex SARS-CoV-2 Variants II Assay obtained CE mark last month to detect key genetic mutations of the viral variants, including L452R, W152C, K417T and K417N.

The variants diagnostic kit can detect Delta, Delta Plus, Kappa, Gamma, Beta and Epsilon variants of the virus in a single reaction.

It can identify ten major Covid-19 variants when used along with Seegene’s variants detection kit, Allplex SARS-CoV-2 Variants I Assay, which was introduced in March.

Recently, Delta and Delta Plus variants have been causing a surge in Covid-19 cases across the world.

The World Health Organisation (WHO) had categorised the Delta variant as the ‘variant of concern’ earlier this year, as it can potentially outcompete other variants quickly.

Apart from the Allplex SARS-CoV-2 Variants II Assay, Seegene has created a research-use-only diagnostic test, Allplex SARS-CoV-2/P681R Assay, which can accurately target the Delta and Delta Plus variants.

Seegene noted the combination of these two assays will aid researchers to differentiate the Delta and Delta Plus variants from multiple other genetic mutations.

Seegene chief technology officer Min-cheol Lee said: “An increased transmissibility, short incubation period and a potential reduction in vaccine efficacy are the characteristics of the Delta and Delta Plus variants.

“While experts and the WHO are largely cautioning the public and governments to remain watchful, I believe that our latest two diagnostic tests will play a key role in the early detection of different viruses and help prevent the further spread of SARS-CoV-2.”

In February, Seegene reported that its less-invasive Covid-19 saliva test is as accurate as the nasopharyngeal specimen test, according to a study.

Separately, GT Molecular has commenced shipment of its sensitive PCR tests to detect the Delta variant.

Apart from SARS-CoV-2 variant tests, GT molecular has tests and PCR kits for influenza A/B detection, which aid researchers and officials in precisely screening community pathogen levels and making robust data-based decisions.

Related Companies

Free Report
img

Navigate your business through the ‘new normal’

COVID-19 continues to dominate headlines the world over. It has already affected our lives forever. The way we work, shop, eat, seek medical advice, and socialize will all be different in the future. Quite how different remains to be seen, but all industries must plan for multiple eventualities.  Faced with an explosion of conflicting information on how to plan and implement successful recovery strategies, decision-makers are in dire need of a single, reliable source of intelligence.   GlobalData’s COVID-19 Executive Briefing gives you access to unparalleled data and insights to successfully navigate the uncertain road to recovery across the world’s largest industries. Understand every aspect of this disruptive theme by delving into: 
  •  COVID-19 infection update, with statistics on the spread, testing by country, as well as the latest data on vaccines and therapeutic developments 
  • Economic impact overview, covering stock market indices, GDP, unemployment rates, policy responses & GlobalData’s economic recovery scorecards 
  • Sector developments, with access to sector insight summaries, cross-sector indices and the leaders and laggards in each industry vertical 
Whatever your company’s imminent strategic plans, the long-lasting impact of COVID-19 must not be overlooked. Find out how to futureproof your business operations – download our report today. 
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. The top stories of the day delivered to you every weekday. A weekly roundup of the latest news and analysis, sent every Friday. The medical device industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU